Evidence map›Paper›PMID 39529512›Full record

ArticleEuropean journal of immunology2025

Type I Interferon Drives a Cellular State Inert to TCR-Stimulation and Could Impede Effective T-Cell Differentiation in Cancer.

Dillon Corvino, Martin Batstone, Brett G M Hughes, Tim Kempchen, Susanna S Ng, Nazhifah Salim, Franziska Schneppenheim, Denise Rommel, Ananthi Kumar, Sally Pearson and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Dillon CorvinoTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-0683-1369
Martin BatstoneRoyal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Brett G M HughesRoyal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Tim KempchenTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.ORCID 0009-0007-0173-2026
Susanna S NgTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Nazhifah SalimTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.ORCID 0009-0002-8581-7783
Franziska SchneppenheimTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Denise RommelTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Ananthi KumarTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Sally PearsonQIMR Berghofer Medical Research Institute, Herston, Australia.
Jason MadoreQIMR Berghofer Medical Research Institute, Herston, Australia.
Lambross T KoufariotisQIMR Berghofer Medical Research Institute, Herston, Australia.
Lisa Maria SteinheuerTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Dilan PathiranaFaculty of Mathematics and Natural Sciences, and the Life and Medical Sciences Institute (LIMES), Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Kevin ThurleyTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Michael HölzelTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Nicholas BorcherdingDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Matthias BraunDepartment of Pediatric Hematology, Oncology and Immunodeficiency, University Childrens Hospital of the Justus-Liebig University Gießen, Gießen, Germany.
Tobias BaldTumor-Immunobiology, Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany.

Funding

Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)DFG Excellence Strategy EXC2047-390873048DFG Excellence Strategy EXC2151-390873048Melanoma Research Alliance 693786
6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) is linked to human papillomavirus (HPV) infection. HPV-positive and HPV-negative HNSCC exhibit distinct molecular and clinical characteristics. Although checkpoint inhibitors have shown efficiency in recurrent/metastatic HNSCC, response variability persists regardless of HPV status. This study aimed to explore the CD8

methodsWe performed simultaneous single-cell RNA and TCR sequencing of CD8

resultsOur analysis identified a subset of CD8

conclusionsISG-enriched CD8

Indexed as

CD8-Positive T-LymphocytesHead and Neck NeoplasmsInterferon Type ILymphocytes, Tumor-InfiltratingReceptors, Antigen, T-CellSquamous Cell Carcinoma of Head and NeckCell DifferentiationFemaleHumansLymphocyte ActivationMalePapillomavirus InfectionsSingle-Cell AnalysisInterferon Type IReceptors, Antigen, T-CellCD8+ T‐cellsHNSCC TILsscRNAseqscTCRseqType I IFN

Identifiers

PMID39529512
PMCPMC11739669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.